Crossmark

Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study

Crossref DOI link: https://doi.org/10.1186/s12888-018-1826-4

Published Online: 2018-08-02

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mamakou, Vasiliki https://orcid.org/0000-0003-0805-9931
Hackinger, Sophie

Zengini, Eleni

Tsompanaki, Evgenia

Marouli, Eirini

Serafetinidis, Ioannis

Prins, Bram

Karabela, Athina

Glezou, Eirini

Southam, Lorraine

Rayner, Nigel W.

Kuchenbaecker, Karoline

Lamnissou, Klea

Kontaxakis, Vassilis

Dedoussis, George

Gonidakis, Fragiskos

Thanopoulou, Anastasia

Tentolouris, Nikolaos

Zeggini, Eleftheria
Funding

Funding for this research was provided by:

Wellcome Trust (098051)
License Information

Text and Data Mining valid from 2018-08-02
More Information

Article History

Received: 26 January 2018

Accepted: 23 July 2018

First Online: 2 August 2018

Ethics approval and consent to participate

: Ethical permission was obtained from Dromokaiteio Psychiatric Hospital Athens ethics committee, Dafni Psychiatric Hospital Athens ethics committee, Hippokrateio General Hospital Athens ethics committee, Laiko General Hospital Athens ethics committee, Eginiteio General Hospital Athens ethics committee. All study participants gave written informed consent following a detailed explanation of the study. This work has been carried out in accordance with the latest version of the Declaration of Helsinki.

: Not applicable

: The authors declare that they have no competing interests

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.